Stoke Therapeutics, Inc. $STOK Shares Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. grew its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 36.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,227,723 shares of the company’s stock after buying an additional 327,451 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Stoke Therapeutics were worth $38,968,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Stoke Therapeutics by 5.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock worth $162,000 after acquiring an additional 1,149 shares during the period. Goldman Sachs Group Inc. lifted its position in Stoke Therapeutics by 21.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock valued at $11,053,000 after purchasing an additional 293,072 shares during the period. Jane Street Group LLC boosted its holdings in Stoke Therapeutics by 125.2% in the 1st quarter. Jane Street Group LLC now owns 26,978 shares of the company’s stock valued at $179,000 after purchasing an additional 15,001 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Stoke Therapeutics by 7.9% in the 2nd quarter. Geode Capital Management LLC now owns 972,921 shares of the company’s stock valued at $11,044,000 after purchasing an additional 70,935 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey increased its position in Stoke Therapeutics by 33.2% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company’s stock worth $108,000 after purchasing an additional 2,384 shares during the period.

Insiders Place Their Bets

In other Stoke Therapeutics news, CFO Thomas Leggett sold 2,382 shares of the business’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total transaction of $74,651.88. Following the sale, the chief financial officer directly owned 10,172 shares in the company, valued at approximately $318,790.48. The trade was a 18.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Jonathan Allan sold 4,628 shares of the business’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $145,041.52. Following the sale, the general counsel owned 28,836 shares in the company, valued at approximately $903,720.24. The trade was a 13.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 69,699 shares of company stock worth $2,526,714. 9.50% of the stock is owned by insiders.

Stoke Therapeutics Trading Up 5.0%

Shares of Stoke Therapeutics stock opened at $33.79 on Thursday. The company has a 50-day moving average of $32.78 and a two-hundred day moving average of $30.37. Stoke Therapeutics, Inc. has a 12-month low of $5.35 and a 12-month high of $40.22. The stock has a market cap of $2.00 billion, a PE ratio of -281.56 and a beta of 1.07.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Wedbush increased their target price on Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 17th. Loop Capital set a $35.00 price objective on Stoke Therapeutics in a report on Monday, January 5th. Needham & Company LLC increased their price objective on Stoke Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. BTIG Research reissued a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a report on Thursday, March 19th. Finally, HC Wainwright boosted their target price on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $41.83.

Stoke Therapeutics Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.